Parexel News (NASDAQ:PRXL)

DateTimeSource
Headline
09/29/201712:58PMBWPamplona Capital Management Completes Acquisition of PAREXEL International
PAREXEL International Corporation (NASDAQ: PRXL) ("PAREXEL" or the "Company"), a leading global biopharmaceutical services company, announced that Pamplona Capital Management, LLP (“Pamplona”) completed its acquisition of PAREXEL today. Pamplona acquired all outstanding shares of PAREXEL for $88.10 per share in cash... More...>>
09/26/20175:49PMPRNUSSix Flags Entertainment and Sterling Bancorp Set to Join S&P MidCap 400; Oil States Intl. and KEMET to Join S&P SmallCap 600
Six Flags Entertainment and Sterling Bancorp Set to Join S&P MidCap 400; Oil States Intl. and KEMET to Join S&P SmallCap 600 PR Newswire NEW YORK, Sept. 26, 2017 NEW YORK, Sept. 26, 2017 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes in the S&P MidCap 400 and S&P SmallCap 600... More...>>
09/18/20179:00AMBWPAREXEL International Receives Shareholder Approval for Proposed Acquisition by Pamplona Capital Management
PAREXEL International Corporation (NASDAQ: PRXL) ("PAREXEL" or the "Company"), a leading global biopharmaceutical services company, announced today that its shareholders, at a special meeting held on September 15, 2017 in Boston, Massachusetts, approved the previously announced proposed acquisition of the Company by certain... More...>>
09/06/20179:00AMBWPAREXEL Launches Real-World Data Service Offering to Drive Value Demonstration of New Treatments
Integrated offering to be provided by new dedicated service group under PAREXEL® Access PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has launched a new end-to-end service offering to provide real-world data insights that help life science... More...>>
08/28/20176:21PMBWPAREXEL International Reports Fourth Quarter and Fiscal Year 2017 Results
Fourth-quarter 2017 service revenue of $557.2 million Fourth-quarter 2017 GAAP diluted EPS of $0.58; adjusted diluted EPS of $1.02 Full-year 2017 service revenue of $2,117.6 million Full-year 2017 GAAP diluted EPS of $2.06; adjusted diluted EPS of $3.32 PAREXEL International Corporation (NASDAQ: PRXL) ("PAREXEL" or the... More...>>
08/21/20174:00PMBWPAREXEL International Announces Date of Fourth Quarter and Fiscal Year 2017 Earnings Release
PAREXEL International Corporation (NASDAQ: PRXL) will release financial results for the Fourth Quarter and Fiscal Year 2017 on Monday, August 28, 2017, after the close of the stock market. PAREXEL will not host a conference call. About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical... More...>>
08/21/20179:00AMBWPAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan
Alliance to drive greater efficiencies across clinical trials in oncology and hematology PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they have formed an alliance to advance clinical development in Japan... More...>>
08/15/20172:59AMPRNUSSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of PAREXEL International Corporation - PRXL
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of PAREXEL International Corporation - PRXL PR Newswire NEW YORK, Aug. 15, 2017 NEW YORK, Aug. 15, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered... More...>>
08/07/20179:00AMBWPAREXEL International Corporation Announces $720 Million Senior Notes Offering by West Street Merger Sub, Inc.
PAREXEL International Corporation (the “Company” or “PAREXEL”) (NASDAQ:PRXL) today announced that West Street Merger Sub, Inc. (“Merger Sub”), an affiliate of Pamplona Capital Management (the “Investor”), formed in connection with the previously announced proposed acquisition of the Company by certain... More...>>
08/01/20179:15AMBWTwo PAREXEL Executives Named to 2017 PharmaVOICE 100
Chief Scientific Officer of PAREXEL and Worldwide Head of The Medical Affairs Company recognized for contributions to life sciences industry PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Sy Pretorius, M.D., Senior Vice President and Chief Scientific... More...>>
07/11/20179:00AMBWPAREXEL Receives CEO Cancer Gold Standard Re-Accreditation
Recognized for commitment to employee health and well-being by CEO Roundtable on Cancer PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the CEO Roundtable on Cancer has again named PAREXEL a CEO Cancer Gold Standard™ employer. The biennial U.S.-based... More...>>
06/26/20179:00AMBWPAREXEL Named to the Forbes America’s Best Employers List for Second Consecutive Year
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that for the second year in a row, Forbes has named the Company to its America’s “Best Employers” list. The list recognizes the top 300 midsized employers and top 500 large employers. Results... More...>>
06/20/20175:44PMPRNUSHarwood Feffer LLP Announces Investigation of PAREXEL International Corporation
Harwood Feffer LLP Announces Investigation of PAREXEL International Corporation PR Newswire NEW YORK, June 20, 2017 NEW YORK, June 20, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of PAREXEL International Corporation ("PAREXEL" or the "Company... More...>>
06/20/20179:49AMDJNHot Stocks to Watch in the U.S. and Canada
Among the companies with shares expected to trade actively in Tuesday's session are Parexel International Corp. (PRXL), Boeing Co. (BA), Apple Inc. (AAPL), and Lipocine Inc. (LPCN). Private-equity firm Pamplona Capital Management reached a deal to buy Parexel for $4.6 billion, the latest in a series of mergers among... More...>>
06/20/20177:05AMBWPAREXEL International Enters Definitive Agreement to Be Acquired by Pamplona Capital Management for $88.10 Per Share in Cash
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Pamplona Capital Management, LLP (Pamplona) today announced that they have entered into a definitive agreement under which Pamplona will acquire all of the outstanding shares of PAREXEL for $88.10 per share in cash... More...>>
06/19/20178:00AMBWPAREXEL Introduces Its Connected Journey™ of Newly Integrated Data-Driven Services to Simplify Drug Development & Commercia...
Features new ForeSite™ clinical trial methodology designed to reliably predict site success As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical... More...>>
06/19/20177:30AMBWPAREXEL’s Alberto Grignolo Named Fellow by Drug Information Association
Honored for contributing to the advancement of health care PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Alberto Grignolo, Ph.D., Corporate Vice President, PAREXEL Consulting, has been named a Fellow by the Drug Information Association (DIA... More...>>
06/15/20178:00AMBWPAREXEL Collaborates with Sanofi to Advance the Use of Wearable Devices in Life Science Industry
Preliminary findings from pilot study validate use of wearable technologies to collect data and manage clinical trials more effectively and efficiently PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced a collaboration with Sanofi to advance the use... More...>>
06/12/20174:01PMBWPAREXEL Experts to Discuss Key Drug Development Insights at DIA 2017
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that several of its experts will discuss key issues facing the industry at the 53rd Drug Information Association (DIA) Annual meeting, held from June 18 to 22, 2017 in Chicago. PAREXEL will hold in-booth... More...>>
06/09/20176:50AMPRNUSHealthcare Stocks on Investors' Radar -- PAREXEL, IDEXX Labs, ICON PLC, and PRA Health Sciences
Healthcare Stocks on Investors' Radar -- PAREXEL, IDEXX Labs, ICON PLC, and PRA Health Sciences PR Newswire NEW YORK, June 9, 2017 NEW YORK, June 9, 2017 /PRNewswire/ -- On Thursday, June 08, 2017, US markets saw a mixed session as 4 sectors closed in green, 3 sectors finished in red, and 2 sectors ended flat for the day... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20171019 07:10:55